MN-166
| Property | Information |
|---|---|
| Drug Name | MN-166 (Ibudilast) |
| FDA Approval | Approved in Japan for post-stroke complications and bronchial asthma; in late-stage clinical development for ALS, Progressive MS, DCM in other regions |
| Used for | Experimental for ALS, Progressive MS, DCM, glioblastoma, CIPN, Long COVID, and substance use disorder |
| Clinical Trial Phase | Phase 3 for ALS and DCM, Phase 3-ready for Progressive MS, Phase 2 for glioblastoma, Long COVID, and substance use disorder |
| Clinical Trial Explanation | Not specified |
| Common Side Effects | Not specified; has been used in Japan with a good post-marketing safety profile |
| OS without | Not specified |
| OS with | Not specified |
| PFS without | Not specified |
| PFS with | Not specified |
| Usefulness Rating | 3 (awaiting research) |
| Usefulness Explanation | Not specified |
| Toxicity Level | Low based on its long-term use in Japan for other conditions |
| Toxicity Explanation | Not specified |
Notes: MN-166 (Ibudilast) is a small molecule compound that inhibits PDE4 and inflammatory cytokines including MIF. It is being developed by MediciNova for a broad range of conditions, including neurodegenerative diseases and glioblastoma, and has been in use in Japan for over 20 years. The drug is in various stages of clinical development in other regions, including Phase 3 for ALS and DCM, and Phase 2 for glioblastoma and substance use disorder.
Links: https://medicinova.com/clinical-development/core/mn-166/, https://www.globenewswire.com/news-release/2023/01/05/2584169/0/en/MediciNova-to-Meet-with-U-S-FDA-to-Discuss-Clinical-Development-of-a-Parenteral-Formulation-of-MN-166-ibudilast.html, https://www.globenewswire.com/news-release/2023/11/19/2584169/0/en/MediciNova-Announces-New-Data-and-Results-of-a-Phase-2.html
From Ben Williams Book: Not specified
